Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)
AssigneeGentium S.R.L.
InventorMassimo IACOBELLI
Life of this patent
Estimating the term…
Abstract
Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (IISCT), more preferably allogeneic hernatopoietic stein cell transplantation. Graft versus Host Disease oldie invention (GVHD) can be acute aGVHD and/or chronic cOVHD, preferably acute.
Claims24
A method of preventing Veno-Occlusive Disease (VOD) comprising administering to a patient at risk of VOD an amount of defibrotide sufficient to reduce the occurrence or severity of VOD.
The method of claim wherein the defibrotide is administered in a dose ranging from 20 to 40 mg/kg/day.
The method of claim , wherein the defibrotide was obtained by extraction from animal tissues.
Dependencies are inferred from the claim text.